Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2025 Results

Mesa Laboratories (MLAB) reported its Q4 and FY25 results, with Q4 revenues increasing 5.5% and full-year revenues up 11.5%; core organic revenue growth was 6.3% and 5.0% respectively. While operating income saw substantial increases, non-GAAP adjusted operating income (AOI) excluding unusual items decreased 18.0% for the quarter, attributed to higher performance-based compensation expenses, but increased 12.3% for the year. CEO Gary Owens highlighted solid momentum and strategic milestones achieved, including the integration of GKE, but also noted potential headwinds from global trade uncertainties.

Analysis

Mesa Laboratories (MLAB) reported robust top-line growth for its fourth fiscal quarter and full fiscal year 2025, with revenues increasing 5.5% to $62.1 million in 4Q25 and 11.5% to $241.0 million for FY25. Core organic revenue growth, a key performance indicator, was strong at 6.3% for 4Q25 and 5.0% for FY25, with all four divisions contributing to organic growth in the fourth quarter. GAAP operating income saw significant year-over-year increases, rising 100.5% in 4Q25 to $1.5 million and 106.0% in FY25 to $16.3 million. However, non-GAAP adjusted operating income (AOI) excluding unusual items presented a mixed picture: it declined 18.0% in 4Q25 to $12.3 million (representing a 19.7% margin), primarily attributed to higher performance-based compensation expenses linked to successful commercial execution in the latter half of the year. For the full fiscal year 2025, non-GAAP AOI excluding unusual items grew 12.3% to $56.7 million, achieving a 23.5% margin, though this was also tempered by increased compensation expenses compared to the prior year. The company demonstrated strong cash generation with $46.8 million in cash from operations and $42.6 million in free cash flow for FY25, facilitating debt reduction of $17.9 million in 4Q25 and lowering the total Net Leverage Ratio to 3.01. Management highlighted several strategic achievements, including the successful integration and outperformance of the GKE acquisition, the launch of Veridose 2.0 in Clinical Genomics, company-wide Salesforce CRM implementation, and accelerated bookings growth. Divisional performance showed the Sterilization and Disinfection Control (SDC) segment as a strong contributor in Q4 with 10.3% core organic growth, while Biopharmaceutical Development (BPD) posted a notable 20.3% core organic growth for FY25. The Clinical Genomics (CG) division saw a 4.4% core organic revenue increase in 4Q25 but experienced a 10.1% decline for FY25, impacted by market conditions in China and US regulatory factors, though a recent favorable court ruling on lab-developed tests offers potential upside. Despite positive operational trends, the company acknowledged potential headwinds from global tariff escalations, though it believes its high recurring revenue base (approximately 75% of FY25 revenues) and strong gross margins provide some insulation.

Key Decisions for Investors

• Investors should note Mesa Laboratories' strong revenue growth and successful execution of strategic initiatives, such as the GKE integration and new product launches, which underpin the positive operational momentum.
• Careful monitoring of non-GAAP adjusted operating income margins is warranted, particularly in light of the Q4 dip due to increased compensation, to ensure sustainable profitability alongside growth.
• While the company has strategies to mitigate tariff impacts, investors should remain vigilant regarding global trade developments and their potential effect on MLAB's international operations and sourcing.
• Further assess the recovery trajectory and long-term outlook for the Clinical Genomics division, considering its Q4 improvement against a challenging full year and the evolving regulatory landscape for lab-developed tests.